Characterizing Breast Cancer Subtypes Using Patient-Derived Organoids to Improve Personalized Treatment

What this Trial Is About

Researchers are investigating breast cancer, focusing on patients who lack targeted therapies such as those with triple-negative breast cancer or those experiencing relapse after previous treatments. The study aims to develop tools to predict how patients respond to chemotherapy and to identify related biomarkers. Patient-derived organoids PDOs, which are lab-grown tumor models preserving key tumor features, are being explored as a promising method for personalized treatment development. The study involves creating and maintaining a living biobank of PDOs that represent various breast cancer subtypes, including ERPR, HER2, and triple-negative breast cancer. These PDOs will be used to assess their similarity to original tumor samples and to test their sensitivity to new and existing therapeutic agents, including splicing-targeting treatments and potential combinations with immunotherapies. The research includes both prospective and retrospective analysis over periods of 36 to 42 months. Participants will be women aged 18 to 70 years diagnosed with primary breast cancer and eligible for tumor surgery. The study evaluates the histological and molecular match between PDOs and patient tumors, as well as PDO responses to treatments through laboratory experiments. Researchers will use these findings to understand chemotherapy resistance and explore new treatment options. The overall study participation includes tumor sample collection and laboratory analysis without direct treatment intervention, and it will continue through mid-2027 for comprehensive data collection and analysis.

Breast Cancer Subtype Characterization Through Patient's Derived Organoids.